• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高通量靶向测序在存档结直肠癌样本中检测到的常见体细胞突变的临床意义

Clinical significance of frequent somatic mutations detected by high-throughput targeted sequencing in archived colorectal cancer samples.

作者信息

Dallol Ashraf, Buhmeida Abdelbaset, Al-Ahwal Mahmoud Shaheen, Al-Maghrabi Jaudah, Bajouh Osama, Al-Khayyat Shadi, Alam Rania, Abusanad Atlal, Turki Rola, Elaimi Aisha, Alhadrami Hani A, Abuzenadah Mohammed, Banni Huda, Al-Qahtani Mohammed H, Abuzenadah Adel M

机构信息

KACST Technology Innovation Center in Personalized Medicine, King Abdulaziz University, P.O. Box 80216, Jeddah, 21589, Kingdom of Saudi Arabia.

Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.

出版信息

J Transl Med. 2016 May 4;14(1):118. doi: 10.1186/s12967-016-0878-9.

DOI:10.1186/s12967-016-0878-9
PMID:27146902
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4857423/
Abstract

BACKGROUND

Colorectal cancer (CRC) is a heterogeneous disease with different molecular characteristics associated with many variables such as the sites from which the tumors originate or the presence or absence of chromosomal instability. Identification of such variables, particularly mutational hotspots, often carries a significant diagnostic and/or prognostic value that could ultimately affect the therapeutic outcome.

METHODS

High-throughput mutational analysis of 99 CRC formalin-fixed and paraffin-embedded (FFPE) cases was performed using the Cancer Hotspots Panel (CHP) v2 on the Ion Torrent™ platform. Correlation with survival and other Clinicopathological parameters was performed using Fisher's exact test and Kaplan-Meier curve analysis.

RESULTS

Targeted sequencing lead to the identification of frequent mutations in TP53 (65 %), APC (36 %), KRAS (35 %), PIK3CA (19 %), PTEN (13 %), EGFR (11 %), SMAD4 (11 %), and FBXW7 (7 %). Other genes harbored mutations at lower frequency. EGFR mutations were relatively frequent and significantly associated with young age of onset (p = 0.028). Additionally, EGFR or PIK3CA mutations were a marker for poor disease-specific survival in our cohort (p = 0.009 and p = 0.032, respectively). Interestingly, KRAS or PIK3CA mutations were significantly associated with poor disease-specific survival in cases with wild-type TP53 (p = 0.001 and p = 0.02, respectively).

CONCLUSIONS

Frequent EGFR mutations in this cohort as well as the differential prognostic potential of KRAS and PIK3CA in the presence or absence of detectable TP53 mutations may serve as novel prognostic tools for CRC in patients from the Kingdom of Saudi Arabia. Such findings could help in the clinical decision-making regarding therapeutic intervention for individual patients and provide better diagnosis or prognosis in this locality.

摘要

背景

结直肠癌(CRC)是一种异质性疾病,具有不同的分子特征,与许多变量相关,如肿瘤起源部位或染色体不稳定性的有无。识别这些变量,尤其是突变热点,通常具有重要的诊断和/或预后价值,最终可能影响治疗结果。

方法

使用Ion Torrent™平台上的癌症热点面板(CHP)v2对99例CRC福尔马林固定石蜡包埋(FFPE)病例进行高通量突变分析。使用Fisher精确检验和Kaplan-Meier曲线分析与生存及其他临床病理参数进行相关性分析。

结果

靶向测序导致识别出TP53(65%)、APC(36%)、KRAS(35%)、PIK3CA(19%)、PTEN(13%)、EGFR(11%)、SMAD4(11%)和FBXW7(7%)中的频繁突变。其他基因的突变频率较低。EGFR突变相对频繁,且与发病年龄较轻显著相关(p = 0.028)。此外,在我们的队列中,EGFR或PIK3CA突变是疾病特异性生存不良的标志物(分别为p = 0.009和p = 0.032)。有趣的是,在TP53野生型病例中,KRAS或PIK3CA突变与疾病特异性生存不良显著相关(分别为p = 0.001和p = 0.02)。

结论

该队列中频繁的EGFR突变以及KRAS和PIK3CA在可检测到或未检测到TP53突变时的不同预后潜力,可能作为沙特阿拉伯王国CRC患者的新型预后工具。这些发现有助于针对个体患者的治疗干预进行临床决策,并在该地区提供更好的诊断或预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c407/4857423/44fe774e2c1e/12967_2016_878_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c407/4857423/e68944ad2d0d/12967_2016_878_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c407/4857423/1a6831d8c9dd/12967_2016_878_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c407/4857423/4855fed6b6d3/12967_2016_878_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c407/4857423/44fe774e2c1e/12967_2016_878_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c407/4857423/e68944ad2d0d/12967_2016_878_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c407/4857423/1a6831d8c9dd/12967_2016_878_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c407/4857423/4855fed6b6d3/12967_2016_878_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c407/4857423/44fe774e2c1e/12967_2016_878_Fig4_HTML.jpg

相似文献

1
Clinical significance of frequent somatic mutations detected by high-throughput targeted sequencing in archived colorectal cancer samples.高通量靶向测序在存档结直肠癌样本中检测到的常见体细胞突变的临床意义
J Transl Med. 2016 May 4;14(1):118. doi: 10.1186/s12967-016-0878-9.
2
Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing.病例匹配的结直肠癌及其转移灶的时空突变谱通过靶向二代测序揭示了异时性肺转移中独特的新发突变。
Mol Cancer. 2016 Oct 18;15(1):63. doi: 10.1186/s12943-016-0549-8.
3
NGS-based oncogenic mutations analysis in advanced colorectal cancer patients improves targeted therapy prediction.基于二代测序的晚期结直肠癌患者致癌基因突变分析可改善靶向治疗预测。
Pathol Res Pract. 2019 Mar;215(3):483-489. doi: 10.1016/j.prp.2018.12.037. Epub 2018 Dec 31.
4
Performance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patients.基于扩增子的靶向下一代测序检测的性能验证及 648 例中国结直肠癌患者的突变分析。
Virchows Arch. 2018 Jun;472(6):959-968. doi: 10.1007/s00428-018-2359-4. Epub 2018 Apr 28.
5
Clinical significance of multiple gene detection with a 22-gene panel in formalin-fixed paraffin-embedded specimens of 207 colorectal cancer patients.207 例结直肠癌患者福尔马林固定石蜡包埋标本中 22 基因panel 多重基因检测的临床意义。
Int J Clin Oncol. 2019 Feb;24(2):141-152. doi: 10.1007/s10147-018-1377-1. Epub 2019 Jan 5.
6
Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.印度结直肠癌患者中KRAS、BRAF、PIK3CA、NRAS、TP53和APC基因突变的患病率及共存情况:基于二代测序的队列研究
Tumour Biol. 2017 Feb;39(2):1010428317692265. doi: 10.1177/1010428317692265.
7
Fecal gene detection based on next generation sequencing for colorectal cancer diagnosis.基于下一代测序的粪便基因检测用于结直肠癌诊断。
World J Gastroenterol. 2022 Jul 7;28(25):2920-2936. doi: 10.3748/wjg.v28.i25.2920.
8
Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.KRAS、NRAS、BRAF和PIK3CA突变对原发性结直肠癌的预后影响:一项基于人群的研究。
J Transl Med. 2016 Oct 13;14(1):292. doi: 10.1186/s12967-016-1053-z.
9
Inter- and intra-tumor profiling of multi-regional colon cancer and metastasis.多区域结肠癌及其转移的肿瘤间和肿瘤内分析
Biochem Biophys Res Commun. 2015 Feb 27;458(1):52-6. doi: 10.1016/j.bbrc.2015.01.064. Epub 2015 Jan 24.
10
Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer.靶向下一代测序在大样本炎性乳腺癌中鉴定出有临床意义的体细胞突变。
Breast Cancer Res. 2018 Aug 7;20(1):88. doi: 10.1186/s13058-018-1007-x.

引用本文的文献

1
Targeted variant prevalence of FBXW7 gene mutation in colorectal carcinoma propagation. The first systematic review and meta-analysis.结直肠癌增殖中FBXW7基因突变的靶向变异患病率。首个系统评价与Meta分析。
Heliyon. 2024 May 22;10(11):e31471. doi: 10.1016/j.heliyon.2024.e31471. eCollection 2024 Jun 15.
2
Molecular pathology of colorectal cancer: The Saudi situation in perspective.结直肠癌的分子病理学:沙特视角。
Saudi Med J. 2023 Sep;44(9):836-847. doi: 10.15537/smj.2023.44.9.20230257.
3
Adherence to the Mediterranean Diet and Perceived Immunity Among the Saudi Population: A Cross-Sectional Study.

本文引用的文献

1
More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds.十多年来酪氨酸激酶抑制剂在实体瘤治疗中的应用:我们所学到的以及未来的展望。
Biomark Insights. 2015 Oct 8;10(Suppl 3):33-40. doi: 10.4137/BMI.S22436. eCollection 2015.
2
Wild-type APC predicts poor prognosis in microsatellite-stable proximal colon cancer.野生型APC预示微卫星稳定的近端结肠癌预后不良。
Br J Cancer. 2015 Sep 15;113(6):979-88. doi: 10.1038/bjc.2015.296. Epub 2015 Aug 25.
3
Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.
沙特人群中地中海饮食的依从性与感知免疫力:一项横断面研究。
Cureus. 2023 Feb 14;15(2):e34963. doi: 10.7759/cureus.34963. eCollection 2023 Feb.
4
Colorectal adenosquamous carcinoma: genomic profiling of a rare histotype of colorectal cancer.结直肠腺样鳞状细胞癌:结直肠癌一种罕见组织学类型的基因组分析。
Virchows Arch. 2023 May;482(5):879-885. doi: 10.1007/s00428-023-03517-6. Epub 2023 Feb 15.
5
Histomorphological and molecular genetic characterization of different intratumoral regions and matched metastatic lymph nodes of colorectal cancer with heterogenous mismatch repair protein expression.结直肠癌肿瘤内不同区域和配对转移淋巴结的组织形态学和分子遗传学特征,其错配修复蛋白表达具有异质性。
J Cancer Res Clin Oncol. 2023 Jul;149(7):3423-3434. doi: 10.1007/s00432-022-04261-1. Epub 2022 Aug 8.
6
A Systematic Review and Meta-analysis on the Occurrence of Biomarker Mutation in Colorectal Cancer among the Asian Population.亚洲人群结直肠癌中生物标志物突变发生的系统评价和荟萃分析。
Biomed Res Int. 2022 Jun 23;2022:5824183. doi: 10.1155/2022/5824183. eCollection 2022.
7
KRAS mutations in patients with colorectal cancer in Libya.利比亚结直肠癌患者中的KRAS突变
Mol Clin Oncol. 2021 Oct;15(4):197. doi: 10.3892/mco.2021.2359. Epub 2021 Jul 30.
8
Identification of Novel Mutations in Colorectal Cancer Patients Using AmpliSeq Comprehensive Cancer Panel.使用AmpliSeq综合癌症检测板鉴定结直肠癌患者的新型突变
J Pers Med. 2021 Jun 9;11(6):535. doi: 10.3390/jpm11060535.
9
Enhancing the landscape of colorectal cancer using targeted deep sequencing.利用靶向深度测序技术改善结直肠癌的治疗效果。
Sci Rep. 2021 Apr 14;11(1):8154. doi: 10.1038/s41598-021-87486-3.
10
Signal transduction pathway mutations in gastrointestinal (GI) cancers: a systematic review and meta-analysis.胃肠道(GI)癌症中的信号转导通路突变:系统评价和荟萃分析。
Sci Rep. 2020 Oct 30;10(1):18713. doi: 10.1038/s41598-020-73770-1.
转移性结直肠癌中 KRAS、NRAS、BRAF 和 PIK3CA 突变的异质性及其对 CAPRI GOIM 试验中治疗的潜在影响。
Ann Oncol. 2015 Aug;26(8):1710-4. doi: 10.1093/annonc/mdv176. Epub 2015 Apr 7.
4
Global cancer statistics, 2012.全球癌症统计数据,2012 年。
CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262. Epub 2015 Feb 4.
5
COSMIC: exploring the world's knowledge of somatic mutations in human cancer.COSMIC:探索全球关于人类癌症体细胞突变的知识。
Nucleic Acids Res. 2015 Jan;43(Database issue):D805-11. doi: 10.1093/nar/gku1075. Epub 2014 Oct 29.
6
Mutant p53 reactivation by small molecules makes its way to the clinic.小分子使突变型 p53 重新激活,为其走向临床铺平了道路。
FEBS Lett. 2014 Aug 19;588(16):2622-7. doi: 10.1016/j.febslet.2014.04.017. Epub 2014 Apr 24.
7
Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer.晚期结直肠癌中具有治疗靶点的预测性和预后生物标志物。
World J Gastroenterol. 2014 Apr 14;20(14):3858-74. doi: 10.3748/wjg.v20.i14.3858.
8
Methylation of the polycomb group target genes is a possible biomarker for favorable prognosis in colorectal cancer.多梳组靶基因的甲基化是结直肠癌预后良好的一个潜在生物标志物。
Cancer Epidemiol Biomarkers Prev. 2012 Nov;21(11):2069-75. doi: 10.1158/1055-9965.EPI-12-0755. Epub 2012 Sep 25.
9
Chromosomal instability (CIN) phenotype, CIN high or CIN low, predicts survival for colorectal cancer.染色体不稳定性(CIN)表型,CIN 高或 CIN 低,可预测结直肠癌的生存。
J Clin Oncol. 2012 Jun 20;30(18):2256-64. doi: 10.1200/JCO.2011.38.6490. Epub 2012 Apr 30.
10
Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications.分子途径:结直肠癌中的微卫星不稳定性:预后、预测和治疗意义。
Clin Cancer Res. 2012 Mar 15;18(6):1506-12. doi: 10.1158/1078-0432.CCR-11-1469. Epub 2012 Feb 2.